Oracle Recognized as a Leader in Everest Group PEAK Matrix® for Life Sciences Clinical Trial Management System (CTMS) Assessment 2024

03.02.25 14:00 Uhr

Werte in diesem Artikel
Aktien

161,88 EUR -1,42 EUR -0,87%

Highlights ease of deployment, value, and extensibility of comprehensive Oracle platform

ORLANDO, Fla. , Feb. 3, 2025 /PRNewswire/ -- SCOPE 2025 – Oracle Life Sciences has been named a 'Leader' in the Everest Group Life Sciences Clinical Trial Management System (CTMS) Products PEAK Matrix® Assessment 2024. This designation underscores Oracle's ongoing commitment to transforming clinical trial management through innovative and cost-effective solutions designed to support healthcare systems and life sciences organizations worldwide.

(PRNewsfoto/Oracle)

As the life sciences industry evolves, driven by increasing trial complexities, regulatory demands, and the need for real-time insights, Oracle continues to redefine the industry standard for CTMS platforms. Oracle's Siebel CTMS platform enables integration with Electronic Health Records (EHR) for seamless data flow between investigators, Contract Research Organizations (CROs), and sponsors, integration with Electronic Data Capture (EDC), and other critical systems, and adherence to diverse regulatory standards.

"Being designated as a 'Leader' by Everest Group in its assessment of our CTMS validates Oracle's mission to deliver cutting-edge technology that accelerates innovation and helps improve outcomes in life sciences," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We are harnessing the full power of Oracle's expertise in data and AI to deliver platforms like CTMS, purpose-built to address the unique challenges of pharma and healthcare systems. Our solution is compliant, secure, cost-effective, and globally adaptable, empowering organizations to drive innovation and efficiency in clinical research and care delivery."

The evaluation highlights Oracle's strengths in providing a comprehensive solution to critical trial management and its abilities to accommodate diverse regulatory requirements globally. The report further highlights Oracle's competitive pricing and seamless integration with critical clinical systems, including EDC, Clinical Data Management Systems (CDMS), electronic trial master file (eTMF), payment, analytics, and regulatory systems.

"The CTMS market is rapidly evolving in response to growing trial complexity, the need for real-time collaboration, and diverse data sources' integration," said Nisarg Shah, practice director, Everest Group. "Providers are now delivering comprehensive trial data management solutions that offer enhanced features to elevate the quality of information provided."

"Oracle's Siebel CTMS platform offers a comprehensive, one-stop-shop solution for clinical trial management, providing flexibility for customization to meet specific organizational needs. Clients value the platform's seamless integration with various critical clinical systems   and analytics solutions. Oracle's extensive global footprint, which helps deliver consistent operations across regions, combined with its expansive capabilities and competitive pricing have positioned Oracle as a Leader in the Life Sciences Clinical Trial Management System (CTMS) Products PEAK Matrix® Assessment 2024."

The Everest Group PEAK Matrix® is a proprietary framework for assessing the relative market success and overall capability of service providers based on performance, experiences, ability, and knowledge. Each service provider is comparatively assessed on two dimensions: market success and delivery capabilities. Market success is measured by revenue, number of clients, and year-over-year growth. Delivery capability is measured by scale of operations, scope, technology and innovation, delivery footprint, and buyer satisfaction. The resulting matrix categorizes service providers as Leaders, Major Contenders, and Aspirants.

To read the full Everest Group PEAK Matrix® report, visit: https://www.everestgrp.com/peak-matrix/healthcare-and-life-sciences/life-sciences-clinical-trial-management-system-ctms-products.html

To read about Oracle and the Everest Group PEAK Matrix® for Electronic Data Capture, visit: https://www.oracle.com/news/announcement/oracle-life-sciences-positioned-as-a-leader-in-the-everest-group-peak-matrix-for-electronic-data-capture-2024-10-24/

About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the life sciences industry to improve patient outcomes. Learn more at oracle.com/lifesciences

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Disclaimer
Licensed extracts taken from Everest Group's PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix® reports do not necessarily provide the full context of our research and analysis.  All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking.  To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.  

About Everest Group  
Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.  

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-recognized-as-a-leader-in-everest-group-peak-matrix-for-life-sciences-clinical-trial-management-system-ctms-assessment-2024-302365733.html

SOURCE Oracle

Ausgewählte Hebelprodukte auf Oracle

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Oracle

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Oracle Corp.

Wer­bung

Analysen zu Oracle Corp.

DatumRatingAnalyst
27.01.2025Oracle BuyJefferies & Company Inc.
03.01.2025Oracle Sector PerformRBC Capital Markets
10.12.2024Oracle HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.12.2024Oracle Sector PerformRBC Capital Markets
10.12.2024Oracle NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
27.01.2025Oracle BuyJefferies & Company Inc.
10.12.2024Oracle BuyUBS AG
10.12.2024Oracle BuyJefferies & Company Inc.
05.12.2024Oracle BuyJefferies & Company Inc.
30.09.2024Oracle KaufenDZ BANK
DatumRatingAnalyst
03.01.2025Oracle Sector PerformRBC Capital Markets
10.12.2024Oracle HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.12.2024Oracle Sector PerformRBC Capital Markets
10.12.2024Oracle NeutralJP Morgan Chase & Co.
23.10.2024Oracle Sector PerformRBC Capital Markets
DatumRatingAnalyst
13.12.2022Oracle SellGoldman Sachs Group Inc.
21.10.2022Oracle SellGoldman Sachs Group Inc.
19.03.2019Oracle VerkaufenDZ BANK
17.09.2015Oracle SellJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
08.01.2015Oracle SellJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Oracle Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"